Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 5/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL688475 | 0.94 | PPARG (0.47) | FFAR1PPARGS1PR1S1PR3PPARA | |
| SCHEMBL6261071 | 0.90 | FFAR1 (0.50) | FFAR1PPARGS1PR1S1PR3PPARA | |
| SCHEMBL4817662 | 0.90 | FFAR1 (0.50) | FFAR1PPARG | |
| SCHEMBL13628910 | 0.90 | S1PR1 (0.50) | S1PR1S1PR3 | |
| SCHEMBL13614219 | 0.88 | CA12 (0.51) | PPARGPPARA | |
| SCHEMBL296830 | 0.87 | S1PR1 (0.54) | S1PR1S1PR3 | |
| SCHEMBL4818486 | 0.87 | S1PR1 (0.54) | FFAR1PPARGS1PR1S1PR3 | |
| SCHEMBL12721394 | 0.86 | S1PR1 (0.56) | S1PR1S1PR3 | |
| SCHEMBL1624956 | 0.86 | S1PR1 (0.56) | S1PR1S1PR3 | |
| SCHEMBL7708027 | 0.84 | FFAR1 (0.48) | FFAR1PPARGS1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326801-B2 | 2-amino-propanol derivatives | NOVARTIS AG (CH) | 2008-02-05 | — | — | US | disclosed |
| US-7326801-B2 | 2-amino-propanol derivatives | NOVARTIS AG (CH) | 2008-02-05 | — | — | US | disclosed |
| US-7326801-B2 | 2-amino-propanol derivatives | NOVARTIS AG (CH) | 2008-02-05 | — | — | US | disclosed |
| EP-1377593-B1 | 2-AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| US-20040147490-A1 | 2-Amino-propanol derivatives | ALBERT RAINER (CH) | 2004-07-29 | — | — | US | disclosed |
| EP-1377593-A2 | 2-AMINO-PROPANOL DERIVATIVES | Novartis AG (CH) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002076995-A2 | 2-AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147490-A1 | 2-Amino-propanol derivatives | CD4, HLA-DRB1, CCR1 | FFAR1 255/4885PPARG 1380/4885S1PR1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.